CD8+ T cells maintain killing of MHC-I-negative tumor cells through the NKG2D-NKG2DL axis.

Saved in:
Bibliographic Details
Title: CD8+ T cells maintain killing of MHC-I-negative tumor cells through the NKG2D-NKG2DL axis.
Authors: Lerner EC; Duke University School of Medicine, Durham, NC, USA.; Department of Biomedical Engineering, Duke University, Durham, NC, USA., Woroniecka KI; Department of Pathology, Duke University Medical Center, Durham, NC, USA., D'Anniballe VM; Duke University School of Medicine, Durham, NC, USA., Wilkinson DS; Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.; Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA., Mohan AA; Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA., Lorrey SJ; Department of Immunology, Duke University Medical Center, Durham, NC, USA., Waibl-Polania J; Department of Pathology, Duke University Medical Center, Durham, NC, USA., Wachsmuth LP; Duke University School of Medicine, Durham, NC, USA.; Department of Pathology, Duke University Medical Center, Durham, NC, USA., Miggelbrink AM; Department of Pathology, Duke University Medical Center, Durham, NC, USA., Jackson JD; Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA., Cui X; Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA., Raj JA; Duke University School of Medicine, Durham, NC, USA., Tomaszewski WH; Department of Immunology, Duke University Medical Center, Durham, NC, USA., Cook SL; Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.; Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA., Sampson JH; Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.; Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA., Patel AP; Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.; Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA.; Center for Advanced Genomic Technologies, Duke University, Durham, NC, USA., Khasraw M; Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA., Gunn MD; Department of Immunology, Duke University Medical Center, Durham, NC, USA.; Department of Medicine, Duke University Medical Center, Durham, NC, USA., Fecci PE; Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA. peter.fecci@duke.edu.; Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA. peter.fecci@duke.edu.
Source: Nature cancer [Nat Cancer] 2023 Sep; Vol. 4 (9), pp. 1258-1272. Date of Electronic Publication: 2023 Aug 03.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101761119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2662-1347 (Electronic) Linking ISSN: 26621347 NLM ISO Abbreviation: Nat Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2662-1347
DOI:10.1038/s43018-023-00600-4